Memantine ER/Donepezil: Difference between revisions
From Pharmacopedia
More actions
| [unchecked revision] | [unchecked revision] |
MDElliottMD (talk | contribs) Create Namzaric combo scaffold |
MDElliottMD (talk | contribs) Sweep: "indications" -> "problems" sitewide terminology update (preserves MedTemplate param name) |
||
| Line 12: | Line 12: | ||
| halflife = ~60–80 h (memantine); ~70 h (donepezil) | | halflife = ~60–80 h (memantine); ~70 h (donepezil) | ||
| bioavailability = ~100% both components | | bioavailability = ~100% both components | ||
| pregnancy = Not relevant (geriatric | | pregnancy = Not relevant (geriatric problem) | ||
| legal = Rx-only in US | | legal = Rx-only in US | ||
| mechanism = Donepezil: reversible AChE inhibitor — increases synaptic acetylcholine. Memantine: uncompetitive low-affinity NMDA receptor antagonist — dampens pathological glutamate overactivation while preserving normal synaptic signaling. Targets two distinct mechanisms in Alzheimer's. | | mechanism = Donepezil: reversible AChE inhibitor — increases synaptic acetylcholine. Memantine: uncompetitive low-affinity NMDA receptor antagonist — dampens pathological glutamate overactivation while preserving normal synaptic signaling. Targets two distinct mechanisms in Alzheimer's. | ||